Revance Therapeutics intends to raise $175m through an underwritten public offering of the shares of its common stock.

Underwriters will be granted a 30-day option to buy and sell an additional 15% of the shares.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Goldman Sachs & Co. and Cowen and Company will serve as book-running managers, while Cooley will serve as legal advisor to Revance.

The funds will be used for general corporate purposes such as clinical trials, research and development, general and administrative expenses, and capital investments.

GW Pharmaceuticals intends to raise $225m through the public offering of American depositary shares (ADS) of its common stock.

Underwriters to the offering have a 30-day option to buy extra ADSs worth $33.75m at the offer price.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The proceeds will be used to fund pre-launch commercialisation activities for Epidiolex, and expanding manufacturing capability for the drug through further clinical development. The funds will also be used for advancing other pipeline opportunities, and working capital and general corporate purposes.

Valeant Pharmaceuticals International has raised C$1.5bn ($1.18bn) through a private placement of unsecured senior notes.

Due 2025, the notes carry a rate of 9% and will provide the company with the necessary funds to pay related fees and expenses and repurchase outstanding notes.

“GW Pharmaceuticals intends to raise $225m through the public offering of American depositary shares (ADS) of its common stock.”

Private equity firm Indiabulls Pharmaceuticals has raised Rs1.55bn ($24m) from Clermont Group, an investment firm based in Singapore.

Indiabulls plans to use the funds to strengthen its growing business.

PMC Group International’s unit PMC Group France has acquired Isochem SAS’s pharmaceutical business.

The acquired business includes drug intermediates and active pharma ingredients’ research, product/process development, regulatory approvals, pilot-scale and full plant-scale production.

The acquired facilities, which are situated at Gennevilliers, Pithiviers, and Vert-Le-Petit, Paris, will be renamed as PMC Isochem SAS.

Teyi Pharmaceutical Group (formerly Guangdong Taicheng Pharmaceutical) has secured the regulatory approval to raise CNY354m ($53.48m) through the private placement of convertible bonds.

Teyi Pharmaceutical plans to end its 2016 share private placement plan.

Humanwell Healthcare (Group) plans to raise CNY2bn ($302m) through a private placement of medium-term notes.

Headquartered in China, Humanwell Healthcare is an integrated healthcare solution provider.